<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
    <channel>
        <title>Boston-BOSLab: Judging Session</title>
        <link>https://video.igem.org/videos/watch/e76643f0-3a94-4490-9e7d-4b5ea4306631</link>
        <description>Tick-borne diseases, including Lyme disease, babesiosis, anaplasmosis, and Powassan virus disease, pose a growing concern as cases rise and new pathogens emerge. Epidermighty developed two approaches using the skin bacterium Staphylococcus epidermidis: an adaptable topical vaccine displaying nonfunctional antigens to target current and emerging pathogens, and protein binders intended to inhibit Dae2, an antimicrobial tick protein. After building vaccine plasmids, we paused this approach for future work and focused on Dae2. We hypothesized Dae2 inhibition could affect tick survival and reduce transmission of multiple diseases; this remains untested. We computationally generated 90 candidate designs and tested five in bacterial and cell-free two-hybrid assays. Results guided improvements, but binder–Dae2 interaction remains unconfirmed. Interviews with 16 stakeholders across patient, clinical, laboratory, environmental, bioethics, and commercial perspectives informed project design and safety. Epidermighty is early-stage research; its safety and effectiveness have not been established.</description>
        <lastBuildDate>Fri, 20 Nov 2026 22:30:00 GMT</lastBuildDate>
        <docs>https://validator.w3.org/feed/docs/rss2.html</docs>
        <generator>PeerTube - https://video.igem.org</generator>
        <image>
            <title>Boston-BOSLab: Judging Session</title>
            <url>https://video.igem.org/client/assets/images/icons/icon-1500x1500.png</url>
            <link>https://video.igem.org/videos/watch/e76643f0-3a94-4490-9e7d-4b5ea4306631</link>
        </image>
        <copyright>All rights reserved, unless otherwise specified in the terms specified at https://video.igem.org/about and potential licenses granted by each content's rightholder.</copyright>
        <atom:link href="https://video.igem.org/feeds/video-comments.xml?videoId=e76643f0-3a94-4490-9e7d-4b5ea4306631" rel="self" type="application/rss+xml"/>
    </channel>
</rss>